S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:KNSA

Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis

$16.91
+0.03 (+0.18%)
(As of 04/19/2024 ET)
Today's Range
$16.56
$17.15
50-Day Range
$16.88
$21.74
52-Week Range
$10.65
$22.09
Volume
375,954 shs
Average Volume
327,628 shs
Market Capitalization
$1.19 billion
P/E Ratio
93.95
Dividend Yield
N/A
Price Target
$30.00

Kiniksa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
77.4% Upside
$30.00 Price Target
Short Interest
Bearish
4.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Kiniksa Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$709,929 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.06) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.94 out of 5 stars

Medical Sector

366th out of 909 stocks

Pharmaceutical Preparations Industry

162nd out of 414 stocks

KNSA stock logo

About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

KNSA Stock Price History

KNSA Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Kiniksa Pharmaceuticals Ltd.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
What Wall Street expects from Kiniksa Pharmaceuticals's earnings
GSK (GSK) Misses Q4 Earnings Estimates
See More Headlines
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/20/2024
Next Earnings (Confirmed)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
297
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$30.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+77.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$14.08 million
Pretax Margin
-6.16%

Debt

Sales & Book Value

Annual Sales
$270.26 million
Book Value
$6.23 per share

Miscellaneous

Free Float
32,320,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
0.27
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Sanj K. Patel (Age 55)
    CEO & Chairman of the Board
    Comp: $1.44M
  • Mr. Eben Tessari (Age 42)
    Senior VP & COO
    Comp: $643.75k
  • Dr. John F. Paolini (Age 59)
    Senior VP & Chief Medical Officer
    Comp: $753.7k
  • Mr. Mark Ragosa C.F.A. (Age 50)
    Senior VP & CFO
  • Mr. Michael R. Megna CPA (Age 53)
    Chief Accounting Officer & Group VP of Finance
  • Ms. Mei Jang
    Senior VP of Technical Operations
  • Rachel Frank
    Associate Director of Investor Relations
  • Mr. Chad Morin
    Senior VP & Chief Compliance Officer
  • Ms. Madelyn Demsky Zeylikman (Age 50)
    SVP, General Counsel & Secretary
  • Ms. Melissa Manno
    Senior VP & Chief Human Resources Officer

KNSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings
or view top-rated stocks.

What is Kiniksa Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 1-year price objectives for Kiniksa Pharmaceuticals' stock. Their KNSA share price targets range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next year. This suggests a possible upside of 77.4% from the stock's current price.
View analysts price targets for KNSA
or view top-rated stocks among Wall Street analysts.

How have KNSA shares performed in 2024?

Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of the year. Since then, KNSA stock has decreased by 3.6% and is now trading at $16.91.
View the best growth stocks for 2024 here
.

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,210,000 shares, an increase of 11.8% from the March 15th total of 2,870,000 shares. Based on an average daily trading volume, of 375,600 shares, the days-to-cover ratio is presently 8.5 days.
View Kiniksa Pharmaceuticals' Short Interest
.

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our KNSA earnings forecast
.

How can I listen to Kiniksa Pharmaceuticals' earnings call?

Kiniksa Pharmaceuticals will be holding an earnings conference call on Tuesday, April 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) released its quarterly earnings results on Wednesday, February, 28th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.15. The business earned $83.40 million during the quarter, compared to the consensus estimate of $72.31 million. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative trailing twelve-month return on equity of 6.12%.

What ETF holds Kiniksa Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 22,347 shares of KNSA stock, representing 2.12% of its portfolio.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

Kiniksa Pharmaceuticals (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.20%), Hennion & Walsh Asset Management Inc. (0.18%) and Allspring Global Investments Holdings LLC (0.09%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel.
View institutional ownership trends
.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KNSA) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners